Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 2:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 5,061 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Placebo, 250 mg CK-2017357, 500 mg CK-2017357; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 15
States / cities: Phoenix, Arizona • Fresno, California • San Francisco, California + 12 more

Conditions: Huntington's Disease
Interventions: SAGE-718; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 29
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more

Conditions: Myasthenia Gravis
Interventions: Placebo, 250 mg CK-2017357, 500 mg CK-2017357; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 15
States / cities: Fresno, California • Orange, California • San Francisco, California + 12 more

Conditions: Solid Tumors
Interventions: dovitinib, fulvestrant; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Las Vegas, Nevada • The Bronx, New York

Conditions: Healthy Subjects
Interventions: Midalozam, Aprocitentan; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Alzheimer's Disease
Interventions: Placebo, Idalopirdine; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 50 Years and older
Enrollment: 858 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 48
States / cities: Phoenix, Arizona • Fayetteville, Arkansas • Anaheim, California + 43 more

Conditions: Healthy
Interventions: Cocoa flavanols I, Control I, Cocoa flavanols II, Control II; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 25 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Davis, California

Conditions: Fragile X Syndrome
Interventions: AFQ056; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 18 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 7
States / cities: Sacramento, California • Decatur, Georgia • Chicago, Illinois + 4 more

Conditions: Neoplasms
Interventions: GSK2636771, Enzalutamide; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 7
States / cities: Duarte, California • Los Angeles, California • Washington D.C., District of Columbia + 3 more

Conditions: Alzheimer's Disease
Interventions: Meganatural-Az Grapeseed Extract, Placebo; Drug
Lead sponsor: Hillel Grossman; Other
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depressive Disorder
Interventions: PDC-1421 Capsule, placebo; Drug
Lead sponsor: BioLite, Inc.; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Lubiprostone, Polyethylene glycol with electrolytes; Drug · Other
Lead sponsor: Augusta University; Other
Eligibility: 50 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Posttraumatic Stress Disorder, Traumatic Brain Injury
Interventions: Methylphenidate Hydrochloride 20 mg, Placebo Capsule, Galantamine 12 mg; Drug
Lead sponsor: INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium; Other
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 7
States / cities: San Diego, California • Boston, Massachusetts • Manchester, New Hampshire + 4 more

Conditions: Primary Biliary Cirrhosis (PBC)
Interventions: Placebo Comparator, Experimental: Seladelpar 50 mg, Experimental: Seladelpar / MBX-8025 200 mg; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 21
States / cities: Phoenix, Arizona • Sacramento, California • Gainesville, Florida + 16 more

Conditions: Hematologic Malignancy
Interventions: BBI608, Dexamethasone, Bortezomib, Imatinib, Ibrutinib; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 8
States / cities: Denver, Colorado • Indianapolis, Indiana • Germantown, Tennessee + 4 more

Conditions: T-cell Lymphoma
Interventions: CPI-818; Drug
Lead sponsor: Corvus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 6
States / cities: Palo Alto, California • Ann Arbor, Michigan • St Louis, Missouri + 3 more

Conditions: Alzheimer's Disease
Interventions: TC-5619, Placebo; Drug
Lead sponsor: Targacept Inc.; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 10
States / cities: Long Beach, California • San Francisco, California • Hallandale, Florida + 7 more

Conditions: Sleep Apnea, Obstructive
Interventions: Seltorexant 40 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 4
States / cities: Atlanta, Georgia • New York, New York • Cincinnati, Ohio + 1 more

Conditions: Osteoarthritis of the Knee
Interventions: HLXL; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 40 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Myelofibroses
Interventions: TP-3654; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Burn Scar, Itch Scarring, Wound
Interventions: Famotidine and 4% topical cromolyn sodium, Placebo; Combination Product · Other
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Healthy
Interventions: TR-701 di-sodium phosphate salt, TR-701 free acid phosphate; Drug
Lead sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Veru-111; Drug
Lead sponsor: Veru Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: Scottsdale, Arizona • Saint Louis Park, Minnesota • Saint Paul, Minnesota + 2 more

Conditions: Generalized Anxiety Disorder, Menopause
Interventions: Black cohosh; Dietary Supplement
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease

Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis

An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective

A Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male Subjects

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil

Daily Intake of Cocoa Flavanols and Arterial Stiffness in Humans

Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)

Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD)

A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder

Efficacy of Lubiprostone in Combination With Standard PEG Preparation

Cognitive REmediation After Trauma Exposure Trial = CREATE Trial

Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease

A Study to Assess the Effect of Seltorexant Compared to Placebo on Respiration During Sleep in Adult Participants With Obstructive Sleep Apnea

Dose Escalation Study Of Chinese Herbs In Osteoarthritis Of The Knee

TP-3654 Food Effect Study

Novel Strategies for Reducing Burn Scar Itch

Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate

COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111

Black Cohosh as Alternative Therapy for Treating Menopause-Related Anxiety